雅 綺麗御守錠
雅 綺麗御守錠 : Product registered in Taiwan. This registration does not constitute authorisation for sale in France or the European Union. It does not demonstrate the safety or efficacy of the product.
TFDA, Taiwan tablets, capsules and medical nutrition registers, retrieved 27 October 2026.
Taiwan Food and Drug Administration (TFDA), Open Government Data License, version 1.0
The foreign register category does not determine the regulatory category of the product in France.
French and European references for recognised ingredients
No point flagged by the rules applied to recognised ingredients.
Unidentified ingredients are not assessed. The absence of a signal does not establish product compliance.
Published composition
| Published ingredient | Published text and quantity | Identified nutrient or substance |
|---|---|---|
| MORINGA | MORINGA | Not identified |
| DEXTRIN | DEXTRIN | Not identified |
| ROYAL JELLY | ROYAL JELLY | Gelée royale |
| VITAMIN B1 (THIAMINE MONONITRATE) | VITAMIN B1 (THIAMINE MONONITRATE) | Vitamine B1 (thiamine) |
| VITAMIN B6 (PYRIDOXINE HYDROCHLORIDE) | VITAMIN B6 (PYRIDOXINE HYDROCHLORIDE) | Vitamine B6 |
| VITAMIN B12 | VITAMIN B12 | Vitamine B12 |
| MALTODEXTRIN | MALTODEXTRIN | Maltodextrine |
| SODIUM CITRATE | SODIUM CITRATE | Not identified |
| CITRIC ACID | CITRIC ACID | Acide citrique |
| CYANOCOBALAMIN | CYANOCOBALAMIN | Vitamine B12 |
| YUZU POWDER | YUZU POWDER | Not identified |
| YUZU FLAVOR | YUZU FLAVOR | Not identified |
| STARCH SODIUM OCTENYL SUCCINATE | STARCH SODIUM OCTENYL SUCCINATE | Not identified |
| VITAMIN E (D-ALPHA TOCOPHEROL) | VITAMIN E (D-ALPHA TOCOPHEROL) | Vitamine E |
| SAFFLOWER YELLOW | SAFFLOWER YELLOW | Not identified |
| MICROCRYSTALLINE α-CELLULOSE | MICROCRYSTALLINE α-CELLULOSE | Not identified |
| ASPARTAME | ASPARTAME | Not identified |
| TARTARIC ACID | TARTARIC ACID | Not identified |
| PALATINOSE | PALATINOSE | Not identified |
| SODIUM BICARBONATE | SODIUM BICARBONATE | Bicarbonate de sodium |
| SODIUM METAPHOSPHATE | SODIUM METAPHOSPHATE | Not identified |
| SUGAR | SUGAR | Not identified |
| α-CYCLODEXTRIN | α-CYCLODEXTRIN | Not identified |
| CALCIUM STEARATE | CALCIUM STEARATE | Not identified |
| SILICON DIOXIDE | SILICON DIOXIDE | Not identified |
The imported data provide no usable daily dosage. No daily dose is estimated and no comparison with dose limits is performed. A published quantity may refer to a preparation or an unspecified unit. Chinese names are retained without translation.
Product record
- Registration number
- 1139019387
- Chinese name
- 雅 綺麗御守錠
- English name
- SPARKLING MORINGA SEED ENERGY TABLET
- Type
- Imported tablets and capsules
- Published status
- Status not provided in this export; the validity date is shown separately
- Licence holder
- 立雅生物科技有限公司
- Registration date
- 2024-05-15
- Published validity end
- 2029-05-15
Original register data
View published fields and their variants
- Product name
- 雅 綺麗御守錠
- Active ingredients
- MORINGA;;DEXTRIN;;MORINGA;;ROYAL JELLY;;VITAMIN B1 (THIAMINE MONONITRATE);;VITAMIN B6 (PYRIDOXINE HYDROCHLORIDE);;VITAMIN B12;;MALTODEXTRIN;;SODIUM CITRATE;;CITRIC ACID;;CYANOCOBALAMIN;;YUZU POWDER;;YUZU POWDER;;DEXTRIN;;YUZU FLAVOR;;DEXTRIN;;YUZU POWDER;;STARCH SODIUM OCTENYL SUCCINATE;;VITAMIN E (D-ALPHA TOCOPHEROL);;SAFFLOWER YELLOW;;SAFFLOWER YELLOW;;MICROCRYSTALLINE α-CELLULOSE;;ASPARTAME;;TARTARIC ACID;;PALATINOSE;;SODIUM BICARBONATE;;SODIUM METAPHOSPHATE;;SUGAR;;MICROCRYSTALLINE α-CELLULOSE;;DEXTRIN;;α-CYCLODEXTRIN;;CALCIUM STEARATE;;SILICON DIOXIDE;;
- Valid until
- 1180515
- Registration number
- 1139019387
- Licence holder
- 立雅生物科技有限公司
- Registration date
- 1130515
- Published reference
- DHC0B390193878
- Published English name
- SPARKLING MORINGA SEED ENERGY TABLET
Official source
View the official register, number 1139019387
Taiwan Food and Drug Administration (TFDA), Open Government Data License, version 1.0
Open Government Data License, version 1.0
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- ROYAL JELLY
Read the warning, when it applies and the studies cited
ROYAL JELLY
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Contraindications
Do not use if you have a history of asthma or allergies (TGA 2001; Leung et al. 1997; Harwood et al. 1996; Laporte et al. 1996; Thien et al. 1996; Leung et al. 1995; Peacock et al. 1995; Bullock 1994).
Sources cited by Health Canada (8)
- Bullock RJ. Fatal royal-jelly induced asthma. Medical Journal of Australia 1994;160:44. PubMed Case report
- Harwood M, Harding S, Beasley R, Frankish PD. Asthma following royal jelly. The New Zealand Medical Journal 1996;109:325. PubMed Case report
- Laporte JR, Ibaanez L, Vendrell L, Ballarin E. Bronchospasm induced by royal jelly. Allergy 1996;51:440. PubMed
- Leung R, Ho A, Chan J, Choy D, Lai CK. Royal jelly consumption and hypersensitivity in the community. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1997;27(3):333-336. PubMed
- Leung R, Thien FC, Baldo B. Royal Jelly-induced asthma and anaphylaxis: clinical characteristics and immunologic correlations. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1995;96:1004-1007. PubMed Case report
- Peacock S, Muray V, Turton C. Respiratory distress and royal jelly. British Medical Journal 1995;311:1472. PubMed Case report
- TGA 2001: Australian Therapeutic Goods Administration. CMEC 28: Complementary Medicines Evaluation Committee, Extracted Ratified Minutes twenty-eight Meeting, 27-28 July 2001. Australian Government Department of Health and Aging, Sydney, Australia; 2001. [Accessed 2025 February 5]. Available from: https://www.tga.gov.au/sites/default/files/cmec-minutes-28.pdf
- Thien FC, Leung R, Baldo BA, Weiner JA, Plomley R, Czarny D. Asthma and anaphylaxis induced by royal jelly. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1996;26(2):216-222. PubMed
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (Leung et al. 1997; Laporte et al. 1996; Thien et al. 1996; Leung et al. 1995; Peacock et al. 1995).
Sources cited by Health Canada (6)
- Laporte JR, Ibaanez L, Vendrell L, Ballarin E. Bronchospasm induced by royal jelly. Allergy 1996;51:440. PubMed
- Leung R, Ho A, Chan J, Choy D, Lai CK. Royal jelly consumption and hypersensitivity in the community. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1997;27(3):333-336. PubMed
- Leung R, Thien FC, Baldo B. Royal Jelly-induced asthma and anaphylaxis: clinical characteristics and immunologic correlations. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1995;96:1004-1007. PubMed Case report
- Peacock S, Muray V, Turton C. Respiratory distress and royal jelly. British Medical Journal 1995;311:1472. PubMed Case report
- Thien FC, Leung R, Baldo BA, Weiner JA, Plomley R, Czarny D. Asthma and anaphylaxis induced by royal jelly. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1996;26(2):216-222. PubMed
- Harwood M, Harding S, Beasley R, Frankish PD. Asthma following royal jelly. The New Zealand Medical Journal 1996;109:325. PubMed Case report
They concern the ingredient, not this product or its dose. They do not replace medical advice.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “雅 綺麗御守錠”, https://compoatlas.com/en/supplements/taiwan/1139019387-sparkling-moringa-seed-energy-tablet, updated 27 October 2026.